Amphastar Pharmaceuticals, Inc. AMPH R2K
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Compounding revenue at 13.0% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 38.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AMPH Amphastar Pharmaceuticals, Inc. R2K | 18.85 | 11.36 | $831.15M | - | 10.14% | 10.39% | 12.99% | 2.39% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 56.67M | 65.19M | 57.92M | 60.40M | 58.39M | 71.04M | 75.54M | 89.69M | 79.79M | 79.05M | 80.14M | 83.38M | 84.69M | 85.81M | 83.43M | 103.02M | 101.66M | 112.20M | 120.37M | 123.47M | 120.13M | 140.02M | 145.71M | 180.56M | 171.84M | 182.39M | 191.21M | - | 170.53M | 174.41M | 191.84M | 183.10M | 171.17M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 85.28M | 87.92M | 93.19M | 97.44M | 100.85M |
| Gross Profit | 13.32M | 17.58M | 33.17M | 24.90M | 31.71M | 27.61M | 19.96M | 22.81M | 26.66M | 20.55M | 20.49M | 16.97M | 26.06M | 29.26M | 34.69M | 30.90M | 32.39M | 35.25M | 33.38M | 36.82M | 33.18M | 36.51M | 44.95M | 47.38M | 51.18M | 55.83M | 63.36M | 58.51M | 73.84M | 72.74M | 108.40M | 90.10M | 95.17M | 101.94M | - | 85.25M | 86.49M | 98.65M | 85.67M | 70.32M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 47.96M | 44.31M | 73.33M | 50.06M | 56.69M |
| Operating Income | -10.26M | -3.75M | - | 4.08M | 10.33M | 5.80M | - | 1.40M | 2.19M | -2.94M | - | -9.78M | -2.94M | 2.55M | - | -3.17M | 973.00K | 2.40M | - | 7.48M | -2.92M | 3.52M | 10.31M | 10.56M | 24.77M | 21.61M | 24.82M | 23.23M | 33.43M | 36.90M | 72.68M | 48.01M | 55.22M | 57.05M | - | 37.29M | 42.18M | 25.32M | 35.61M | 13.63M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 52.35M | 61.85M | 43.56M | 54.53M | 33.10M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.29M | 6.28M | 6.28M | 6.63M | 6.55M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 30.86M | 39.34M | 21.51M | 31.91M | 10.05M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.58M | 8.30M | 4.16M | 7.49M | 3.63M |
| Net Income | -6.65M | -3.01M | 7.53M | 2.49M | 6.89M | 3.89M | -2.74M | 893.00K | 1.97M | 99.00K | 1.47M | -7.14M | -2.85M | 2.39M | 1.87M | 868.00K | 47.79M | 1.31M | -1.03M | 3.95M | -192.00K | 3.92M | 5.04M | 7.77M | 29.55M | 24.25M | 17.35M | 15.87M | 26.03M | 26.12M | 49.22M | 43.18M | 37.95M | 40.43M | - | 25.29M | 31.03M | 17.35M | 24.43M | 6.42M |
| Diluted EPS | -0.15 | -0.07 | 0.16 | 0.05 | 0.15 | 0.08 | -0.06 | 0.02 | 0.04 | 0.00 | 0.02 | -0.15 | -0.06 | 0.05 | 0.04 | 0.02 | 0.96 | 0.03 | -0.02 | 0.08 | 0.00 | 0.08 | 0.10 | 0.16 | 0.59 | 0.47 | 0.33 | 0.30 | 0.50 | 0.49 | 0.91 | 0.81 | 0.73 | 0.78 | - | 0.51 | 0.64 | 0.37 | 0.51 | 0.14 |
| R&D Expense | 10.73M | 11.12M | - | 8.61M | 10.59M | 9.72M | - | 11.25M | 10.73M | 10.07M | - | 14.03M | 15.46M | 11.34M | - | 14.61M | 16.00M | 18.61M | - | 15.30M | 16.15M | 17.64M | 14.77M | 18.12M | 10.76M | 16.22M | 22.80M | 18.51M | 19.82M | 16.84M | 16.66M | 17.04M | 17.65M | 21.08M | - | 20.10M | 20.08M | 22.35M | - | 26.74M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 255.16M | 240.18M | 294.67M | 322.36M | 349.85M | - | 498.99M | 644.39M | 731.97M | 719.89M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | 250.13M | 293.27M | 358.11M | 363.83M |
| Gross Profit | 90.30M | 86.96M | 51.26M | 77.35M | 104.20M | 90.51M | 106.98M | 131.92M | 143.34M | - | 248.86M | 351.12M | 373.86M | 356.06M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | 141.36M | 154.13M | 168.44M | 215.65M |
| Operating Income | 25.40M | 17.49M | -17.98M | -6.90M | 15.38M | -1.27M | -8.62M | -39.00K | 10.95M | - | 107.50M | 196.99M | 205.42M | 140.40M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | 146.16M | 240.29M | 277.31M | 212.31M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | 1.85M | 27.16M | 30.34M | 25.48M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | 116.04M | 171.36M | 189.76M | 123.62M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | 23.48M | 31.83M | 29.67M | 25.53M |
| Net Income | 18.09M | 11.86M | -10.70M | -2.79M | 9.82M | 3.65M | -5.74M | 48.94M | 1.40M | - | 91.39M | 137.54M | 159.52M | 98.09M |
| Diluted EPS | 0.46 | 0.31 | -0.25 | -0.06 | 0.21 | 0.08 | -0.12 | 0.98 | 0.03 | - | 1.74 | 2.60 | 3.06 | 2.03 |
| R&D Expense | 31.16M | 33.02M | 28.87M | 37.27M | 41.52M | 43.50M | 57.56M | 68.85M | 67.23M | 60.93M | 74.77M | 73.74M | 73.91M | 85.84M |
Compounded Sales Growth
| 5 Years: | 12.99% |
| 1 Year: | 0.40% |
Compounded Profit Growth
| 5 Years: | 2.39% |
| 1 Year: | -72.50% |
Stock Price Performance
| 1 Year: | -26.68% |
| 6 Months: | -31.92% |
| 3 Months: | -6.82% |
| 1 Month: | -12.85% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 338.75M | 389.37M | 390.14M | 427.74M | 451.07M | 513.56M | 586.97M | 631.24M | - | 741.99M | 1.51B | 1.58B | 1.63B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | 378.32M | 489.60M | 534.07M | 636.02M |
| Cash & Equivalents | 53.74M | 50.21M | 53.59M | 67.83M | 66.07M | 72.35M | 65.59M | 86.34M | 73.69M | 92.64M | - | 156.10M | 144.30M | 151.61M | 170.18M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | 103.58M | 105.83M | 153.74M | 176.89M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | 88.80M | 114.94M | 136.29M | 143.56M |
| Total Liabilities | - | - | 87.20M | 107.51M | 94.63M | 98.48M | 117.34M | 149.20M | 159.44M | 182.51M | - | 213.33M | 873.49M | 845.17M | 840.49M |
| Current Liabilities | - | - | 65.40M | 62.59M | 59.95M | 60.62M | 67.19M | 106.83M | 90.01M | 112.20M | - | 94.86M | 225.41M | 173.76M | 158.16M |
| Long Term Debt | - | - | - | 42.68M | 40.30M | 36.03M | 45.72M | 49.10M | 46.32M | 45.92M | - | 72.84M | 589.58M | 601.63M | 608.75M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | 102.58M | 623.64M | 650.55M | 656.00M |
| Total Equity | 208.52M | 233.44M | 251.54M | 281.86M | 295.51M | 329.25M | 333.74M | 332.44M | 381.37M | 402.31M | - | 528.66M | 639.42M | 732.30M | 788.80M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | 58.11M | 59.39M | 60.85M | 61.78M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | 10.68M | 38.56M | 39.21M | 38.19M | 41.76M | 57.27M | - | 89.18M | 183.50M | 213.39M | 156.12M |
| Investing Cash Flow | - | - | - | -16.93M | -39.50M | -36.89M | -42.18M | -50.53M | -36.41M | - | -32.78M | -649.12M | -124.93M | -70.33M |
| Financing Cash Flow | - | - | - | 2.24M | 7.14M | -7.72M | 25.01M | -3.78M | -2.25M | - | -26.44M | 454.09M | -80.95M | -67.42M |
| Capital Expenditure | -23.13M | -17.64M | -20.50M | -16.00M | -21.38M | -35.10M | -46.81M | -41.55M | -33.85M | - | -24.03M | -38.17M | -41.04M | -37.13M |
| Free Cash Flow | - | - | - | -5.32M | 17.18M | 4.11M | -8.62M | 207.00K | 23.41M | - | 65.15M | 145.34M | 172.34M | 118.98M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | 29.96M | -11.52M | 7.50M | 18.36M |
| Share Buybacks | 811.00K | 199.00K | 345.00K | 9.87M | 9.91M | 30.75M | 25.05M | 22.29M | 24.43M | 28.87M | 39.91M | 58.14M | 85.46M | 75.59M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | 40.8% | 37.7% | 36.3% | 40.9% | 41.0% | - | 49.9% | 54.5% | 51.1% | 49.5% |
| Operating Margin % | - | - | - | - | 6.0% | -0.5% | -2.9% | -0.0% | 3.1% | - | 21.5% | 30.6% | 28.1% | 19.5% |
| Net Margin % | - | - | - | - | 3.8% | 1.5% | -1.9% | 15.2% | 0.4% | - | 18.3% | 21.3% | 21.8% | 13.6% |
| ROE % | 7.8% | 4.7% | -3.8% | -0.9% | 3.0% | 1.1% | -1.7% | 12.8% | 0.3% | - | 17.3% | 21.5% | 21.8% | 12.4% |
| ROCE % | - | 6.4% | -5.5% | -2.1% | 4.2% | -0.3% | -2.1% | -0.0% | 2.1% | - | 16.6% | 15.3% | 14.6% | 9.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 12.30% | 5.42M | $102.19M |
| 2 | Dimensional Fund Advisors LP | 4.60% | 2.03M | $38.23M |
| 3 | State Street Corporation | 3.65% | 1.61M | $30.30M |
| 4 | Vanguard Capital Management LLC | 3.50% | 1.54M | $29.10M |
| 5 | TD Asset Management, Inc | 3.49% | 1.54M | $29.05M |
| 6 | Fuller & Thaler Asset Management Inc. | 3.16% | 1.40M | $26.30M |
| 7 | Marshall Wace LLP | 2.33% | 1.03M | $19.33M |
| 8 | American Century Companies Inc | 2.31% | 1.02M | $19.18M |
| 9 | Geode Capital Management, LLC | 2.21% | 976.65K | $18.41M |
| 10 | Boston Trust Walden Corporation | 2.14% | 944.79K | $17.81M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AMPH